Wikipedia -WSS

Wikipedia

author：entertainment 2025-08-11 09:49:14 - browse：39441

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — Illustration: Alex Hogan/STAT; Photo: Eisai via AP

Medicare has officially expanded its coverage policy for brain scans that detect a brain plaque associated with Alzheimer’s disease, the agency announced on Friday.

Amyloid PET scans are important tools to help determine whether patients with mild cognitive impairment are good candidates for new Alzheimer’s drugs, including Eisai and Biogen’s drug Leqembi, which means there will likely be an increase in demand for the scans as uptake increases.

Previously, Medicare limited coverage for the drug to patients enrolled in clinical studies, and only covered one scan in a patient’s lifetime. The new coverage policy removes those restrictions and delegates decisions about how many scans to cover to regional Medicare administrators.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： CDC's new outbreak response network to include Northeastern

WSS

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Medical student insurance fails on mental health care coverage

CDC advisers recommend seasonal use of Pfizer RSV shot

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Venture capitalist Bob Kocher on the state of digital health

knowledge

Wikipedia

hotspot

The cancer drug shortage isn’t new — and neither are the solutions

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Hollywood unions extend contract negotiations for actors

Criminal prosecution for violating HIPAA: an emerging threat

As demand for Covid shots wanes, Moderna seeks its next success

Readers respond to H5N1 and livestock movements, and more

State Dept. review finds Biden bears some blame for Afghanistan failures

Microbiome research is starting to find links to chronic diseases

Bright Health sells Medicare Advantage business to Molina

Senators: Long

leisure time

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Intarcia’s device

EpiPen alternative approval delay highlights citizen petition issue

Ukraine and a new approach to mental health in war

FDA panel to weigh approval of NurOwn, controversial ALS drug

CDC's new outbreak response network to include Northeastern

knowledge

leisure time

focus

explore